State Board of Medical Examiners

Special Call Business Meeting

NOTICE IS HEREBY GIVEN, pursuant to LSA-R.S. 42:19(A), that the Louisiana State Board of Medical Examiners (the "Board"), within the Department of Health and Hospitals, State of Louisiana, shall convene a special meeting of the Board at 9:00 a.m., Monday, November 9, 2015, at the offices of the Board, 630 Camp Street, New Orleans, Louisiana. The agenda of such meeting can be found here. AGENDA



Unprofessional Conduct Rules

NOTICE-On October 20, 2015 the Louisiana Register published certain amendments to the Board’s rules on unprofessional conduct, LAC 46:XLV.7603. The publication inadvertently included wording that the Board had instructed be removed e.g., a physician shall “b. not hold himself or herself out as a specialist in an area of medical practice unless the physician has successfully completed a residency or fellowship training program, which is accredited by the American Council on Graduate Medical Education of the American Medical Association, the American Osteopathic Association, or the Royal College of Physicians and Surgeons of Canada.”

The cited language was previously removed from this rulemaking effort by the Board. See: Potpourri Section of the July 2015 edition of the Register (LR 41:1416), whereat the Board noted that “After further review the board has decided to defer proceeding at this time on the amendments original proposed in §7603A.9 (e.g., holding one’s self out as a specialist) and proceed only with the proposed amendments to §7603A.11.”

The Register has agree to reprint the corrected Rule removing the cited language, with an explanatory note, in the November edition of the Register.  



Online Renewal Applications

All licensees who are scheduled to renew starting in November 2015 will renew on line.  Please go to our web site at and click on the “Apply for or Renew a License” link on the home page.

If you need help registering or completing the application send us an email at or call us at (504) 568-7303 between 8 AM and 5 PM central time weekdays.


Notice to Physician Assistants

Notice; Physician Assistants—Act 453 of the 2015 Session of the Louisiana Legislature amended the law governing physician assistants (PAs) to include, among other items, Schedule II CDS within the drugs that could be delegated to a PA by a supervising physician (SP). A rule-making effort to conform the Board’s existing rules to the changes is in development. In the interim, the law supersedes the rules where there is a disparity. A PA whose SP wishes to delegate Schedule II authority should complete and return to the Board an updated Notice of Intent to practice (available on this website).



Underreporting of Infectious Diseases

Recent outbreaks of viral meningitis and salmonella in Louisiana have the state’s Infectious disease epidemiology department concerned about the underreporting of certain infectious diseases.  While many of these conditions do get reported to them from labs or the infection control department of hospitals, we would like to remind health practitioners of their individual responsibility in this matter. 

Dr. Raoult Ratard, the state epidemiologist realizes that physicians and others are busy professionals and will not report every case of infectious disease.  However, he and his associates in the department of infectious disease epidemiology do hope that health professionals use their common sense.  If, for example, a physician, nurse or PA sees a child with diarrhea and bloody stool and it is mentioned that various children in the class are suffering from the same condition, a call to the hotline is in order.  The faster the department is made aware of a potential problem, the faster it can operate to locate the source of a food borne illness or a dangerous respiratory or other condition and prevent further morbidity and/or mortality.

For further information on what diseases are reportable under the Sanitary Code and how soon they must be reported after diagnoses, go to and download this helpful information.  (You may want to post this one page document in your office.) The 24 hour hotline number to report infectious diseases or suspected outbreaks is 800-256-2748.


Guidance For Physicians On Safe Purchase Of Drugs From Pharmaceutical Distributors

 GUIDANCE FOR PHYSICIANS ON SAFE PURCHASE OF DRUGS FROM PHARMACEUTICAL DISTRIBUTORS Health care providers can help protect the public health and reduce potential legal liability by avoiding purchasing prescription drugs that do not comply with U.S. regulatory requirements.  To help ensure safe drug purchasing from pharmaceutical distributors, FDA recommends that health care providers and their staff do the following:

  1. Ensure you receive FDA-approved prescription Drugs.Buying directly from the manufacturer or a wholesale drug distributor licensed in your state will reduce the chances of unsafe of ineffective drugs reaching your patients. (check if state-approved at
  2. Beware of offers too good to be true.Aggressive marketing tactics and deep discounts on prescription drugs may indicate the products are stolen, counterfeit, substandard or unapproved
  3. Buy only from state-licensed wholesale drug distributors.
  4. Caution:check for these signs that a prescription may be unsafe, ineffective or fake:
    1. Label is not in English
    2. Packaging looks slightly different from the FDA approved product
    3. Product name differs from the name of the FDA approved drug
    4. Dosing recommendations are unfamiliar
    5. Safety information or warnings are missing
    6. Dosage form or administration is different
  5. Pay close attention to patient feedback.If several patients report that they are experiencing a new side effect or lack of therapeutic effect form the same product, consider that the drug may be substandard or counterfeit.Health care providers and patients are encourages to report any adverse events or suspect medication to the FDA’s MedWatch Safety Information and Adverse Event Reporting Program either online at or by calling 1-800-332-1088.


Purchasing Safe Drugs and Devices from an Approved Source




Under the Drug Supply Chain Security Act (21 U.S.C. 351 et seq.), as of January 1, 2015, all healthcare providers who dispense or administer prescription drugs to patients are required to purchase their prescription drug products only from authorized trading partners licensed by or registered with the state or federal government. This will help protect patients from being harmed by potentially dangerous and illegal drug products.


The FDA is committed to promoting and protecting the public health by helping to ensure that only safe, effective, and high-quality drugs and devices are available to the American public. Health care providers and patients are encouraged to report any suspicious medical products to FDA's Office of Criminal Investigations Physician offices should be wary of mass advertising campaigns via “blast faxes,” phone calls, direct email, and online marketing for the sale of physician administered drugs and injections.


The Louisiana Board of Wholesale Drug Distributors (LBWDD) is the state agency charged with the responsibility to safeguard life and health and to promote the public welfare by licensing and regulating all entities engaged in the wholesale distribution of controlled or legend drugs or devices in/into the state of Louisiana.


To verify that a vendor you buy drugs or devices from is licensed by the LBWDD, go to: